Note: Descriptions are shown in the official language in which they were submitted.
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
ORGANIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY OR ALLERIC CONDITIONS
The present invention relates to organic compounds, their preparation and
their use
as pharmaceuticals.
In a first aspect, the present invention provides compounds of formula (I)
R2 R3 O
R' Y W N,
\ 7
X R
~I)
(R4)m (RS)n
in free or pharmaceutically acceptable salt form,
wherein
R' is selected from R'aS-, R'aO- and R'aNR9-, wherein R'a is
Rlb Rlc
Ra0
O
wherein
R'b and R'c are independently selected from H, C,-C8-alkyl, and together with
the
carbon atom to which they are attached form a divalent C3-Cg-cycloaliphatic
group;
R2 and R3 are independently selected from H, C,-C8-alkyl, and together with
the
carbon atom to which they are attached form a divalent C3-C8-cycloaliphatic
group;
R4 and R5 are independently selected from H, halogen, C,-C8-alkyl, C,-C8-
haloalkyl, a
C3-C15-carbocyclic group, nitro, cyano, S02R5a, C,-C8-alkylcarbonyl,
C,-C8-alkoxycarbonyl, C,-C8-alkoxy, C,-C8-haloalkoxy, -SR5b, carboxy, carboxy-
C,-C8-alkyl, amino, amino(C,-C8-alkyl), C,-CB-alkylamino(C,-C$-alkyl),
di(C,-C8-alkyl)amino(C,-C8-alkyl), C,-C8-alkylamino, di(C,-C8-alkyl)amino,
SO2NR5cR5d, -C(O)NR5eR5i, C,-C8-hydroxyalkyl, NR59SO2R5h, NR5i(CO)R5',
SOR5k, a C6-C15-aromatic carbocyclic group and a 4- to 10-membered
-1-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
heterocyclic group having one or more heteroatoms selected from the group
consisting of oxygen, nitrogen and sulphur;
RSa, Rsk and R5b are independently selected from C,-C8-alkyl, C,-C8-
hydroxyalkyl,
C,-C8-alkylamino(C,-Ca-alkyl), di(C,-C8-alkyl)amino(C,-CB-alkyl),
C,-C8-cyanoalkyl, a C3-C,5-carbocyclic group, C,-C8-haloalkyl and a 4- to
10-membered heterocyclic group having one or more heteroatoms selected from
the group consisting of oxygen, nitrogen and sulphur;
R5o R5d, R5e and R5f are, independently, H, C,-C8-alkyl, C,-C8-hydroxyalkyi,
C,-C8-alkylamino(C,-C8-alkyl), di(C,-C$-alkyl)amino(C,-C8-alkyl),
C,-C8-cyanoalkyl, a C3-C,5-carbocyclic group, C,-C8-haloalkyl, a 4- to
1 0-membered heterocyclic group having one or more heteroatoms selected from
the group consisting of oxygen, nitrogen and sulphur, or, together with the
nitrogen atom to which they are attached, form a C4-C,o-heterocyclic group;
R59 and R5i are independently selected from H, C,-C8-alkyl, C,-C8-
hydroxyalkyl,
C,-C8-alkylamino(C,-C8-alkyl), di(C,-C8-alkyl)amino(C,-C$-alkyl),
C,-C8-cyanoalkyl, a C3-C75-carbocyclic group, C,-C$-haloalkyl and a 4- to
10-membered heterocyclic group having one or more heteroatoms selected from
the group consisting of oxygen, nitrogen and sulphur;
R5h and R5' are independently selected from C,-C$-alkyl, a C3-C15-carbocyclic
group, a
4- to 10-membered heterocyclic group having one or more heteroatoms selected
from the group consisting of oxygen, nitrogen and sulphur, C,-C8-hydroxyalkyl,
amino(C,-C8-alkyl), C,-Ca-alkylamino(C,-C8-alkyl), di(C,-C8-
alkyl)amino(C,-Cs-alkyl) and C,-C8-cyanoalkyl;
R6 and R', together with the nitrogen to which they are attached, form a 4- to
10-membered heterocyclic group containing the indicated nitrogen atom as a
ring
heteroatom and optionally at least one ring heteroatom selected from the group
consisting of nitrogen, oxygen and sulphur;
R8 is selected from H, C,-C8-alkyl, C3-C15-cycloalkyl, C,-C$-alkyl(C6-C15-
aromatic
carbocyclic group) and C6-C15-aromatic carbocyclic group;
R9 is selected from H, C,-Ca-alkyl, C3-C15-cycloalkyl, C,-Ca-alkyl(C6-C15-
aromatic
carbocyclic group) and C6-C15-aromatic carbocyclic group;
X is -CH2-, -CH(C,-C8-alky-)-, -CO-, -CH(OH)-, -CH(OC,-C$-alkyl)-, -
C(halogen)2-, -0-,
-S-, -SO-, -SOZ- or a bond;
Y is -0-, -S-, -CH2- or -NR'(C,-C$-alkyl)-;
-2-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
m and n are each, independently, an integer selected from 0-3;
v is an integer selected from 1-3; and
w is an integer selected from 0-3.
Rlb RIc
HO
~
According to formula (I), R' is R'aO-, where R'a is 0 and R'b and R' are H.
According to formula (I), R2 and R3 are, independently, H or C,-C8-alky, e.g.
methyl.
According to formula (I), R6 and R7, together with the nitrogen to which they
are attached,
form a 4- to 10-membered heterocyclic group containing the indicated nitrogen
atom as a
ring heteroatom and optionally at least one ring heteroatom selected from the
group
consisting of nitrogen, oxygen and sulphur, which ring is unsubstituted or
substituted by C,-
C4-alkyl, e.g. methyl, cyano-C,-C4-alkyl, C,-C8-alkylamino or di(C,-C8-
alkylamino). Examples
of the 4- to 10-membered heterocyclic group include, but are not limited to, a
pyrrolidine ring,
a morpholine ring, a piperazine ring, and a piperidine ring. Where the 4- to
10-membered
heterocyclic group is a piperazine ring the piperazine ring is suitably
substituted by methyl or
a propionitrile group.
According to formula (I), R12 and R13 are, independently, H, or halogen.
According to formula (I), X is suitably -CH2-, -S-, -SO- or -SO2-.
According to formula (I), Y is suitably -0-;
According to formula (I), v is 1;
According to formula (I), w is an integer selected from 0-3.
-3-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Another embodiment of the present invention provides compounds, in free or
pharmaceutically acceptable salt form, wherein the compound is of formula (la)
R 2 R3 O
HO
,~'CO O W N~R6\
O X R, J
*12 O ~~ RR1s
wherein
R2 and R3 are, independently, H or C,-C$-alkyl;
R6 and R', together with the nitrogen to which they are attached, form a 4- to
10-membered heterocyclic group containing the indicated nitrogen atom as a
ring
heteroatom and optionally at least one ring heteroatom selected from the group
consisting of
nitrogen, oxygen and sulphur, which ring is unsubstituted or substituted by C,-
C4-alkyl or
cyano-C,-C4-alkyl;
X is -CH2-, -S-, -SO- or -SO2-, preferably -CH2-.
R12 and R13 are, independently, H, or halogen; and
w is 1.
In another embodiment, the present invention provides for the use of a
compound of
formula (I) in any of the aforementioned embodiments, in free or
pharmaceutically acceptable
salt form, for the manufacture of a medicament for the treatment of an
inflammatory or
allergic condition, particularly an inflammatory or obstructive airways
disease.
It is understood that any and all embodiments of the present invention may be
taken
in conjunction with any other embodiment to describe additional embodiments of
the present
invention. Furthermore, any elements of an embodiment are meant to be combined
with any
and all other elements from any of the embodiments to describe additional
embodiments.
-4-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Definitions
Terms used in the specification have the following meanings:
"Optionally substituted", as used herein, means the group referred to can be
substituted at one or more positions by any one or any combination of the
radicals listed
thereafter.
"Halogen" or "halo" may be fluorine, chlorine, bromine or iodine; preferably
it is
bromine or chlorine or fluorine.
"C1-CB-Alkyl" denotes straight-chain or branched C,-C8-alkyl, which may be,
e.g.,
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
straight- or branched-
pentyl, straight- or branched-hexyl, straight- or branched-heptyl or straight-
or branched-
octyl. Preferably, C,-C8-alkyl is C,-C4-alkyl.
"C3-C15-Carbocyclic group", as used herein, denotes a carbocyclic group having
3- to
15-ring carbon atoms, e.g., a monocyclic group, either cycloaliphatic, such as
a
C3-C$-cycloalkyl, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl or
cyclooctyl; or aromatic, such as phenyl; or a bicyclic group, such as
bicyclooctyl, bicyclononyl
including indanyl and indenyl, and bicyclodecyl including naphthyl.
Preferably, the
C3-C15-carbocyclic group is a C3-C,o-carbocyclic group, e.g., phenyl or
naphthyl. The
C3-C15-carbocyclic group can be substituted with 1-3 substituents or
unsubstituted. Preferred
substituents include halo, cyano, amino, nitro, carboxy, C,-Ca-alkyl, C,-C$-
haloalkyl,
C,-C8-alkoxy, C,-C8-alkylcarbonyl, C,-C8-alkoxycarbonyl, C,-C8-haloalkoxy,
carboxy-C,-C8-
alkyl, C,-C8-alkylamino, di(C,-C8-alkylamino), C,-C8-alkylsulfonyl, -SO2NH2,
(C,-C8-alkylamino)sulfonyl, di(C,-C8-alkyl)aminosulfonyl, aminocarbonyl,
C,-C8-alkylaminocarbonyl and di(C,-Ca-alkyl)aminocarbonyl, a C3-C,o-
carbocyclic group and
a 5- to 12-membered heterocyclic group having at least one ring heteroatom
selected from
nitrogen, oxygen and sulphur.
"C6-C15-Aromatic carbocyclic group", as used herein, denotes a divalent
aromatic
group having 6- to 15-ring carbon atoms, e.g., phenylene, naphthylene or
anthrylene. The
C6-Ct5-aromatic group can be substituted with 1-3 substituents or can be
unsubstituted.
Preferred substituents include halo, cyano, amino, nitro, carboxy, C,-C8-
alkyl, halo-C,-CB-
alkyl, C,-Ce-alkoxy, C,-C8-alkylcarbonyl, C,-C8-alkoxycarbonyl, C,-Ce-
haloalkoxy, carboxy-
-5-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
C,-C$-alkyl, C,-C8-afkylamino, di(C,-C8-alkylamino), C,-CB-alkylsulfonyl, -
SO2NH2,
(C,-C8-alkylamino)sulfonyl, di(C,-C8-alkyl)aminosulfonyl, aminocarbonyl,
C,-C8-alkylaminocarbonyl and di(C,-C8-alkyl)aminocarbonyl, a C3-C15-
carbocyclic group and
a 5- to 12-membered heterocyclic group having at least one ring heteroatom
selected from
nitrogen, oxygen and sulphur.
"Divalent C3-C$-cycloaliphatic" denotes cycloalkylene having 3- to 8-ring
carbon
atoms, e.g., a monocyclic group, such as a cyclopropylene, cyclobutylene,
cyclopentylene,
cyclohexylene, cycloheptylene or cyclooctylene, any of which can be
substituted by one or
more, usually one or two, C,-C4-alkyl groups; or a bicyclic group, such as
bicycloheptylene or
bicyclooctylene. Preferably "C3-Ca-cycloalkylene" is C3-C5-cycloalkylene,
e.g.,
cyclopropylene, cyclobutylene or cyclopentylene.
"C,-C8-Alkoxy" denotes straight-chain or branched C,-C8-alkoxy which may be,
e.g.,
methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-
butoxy,
straight- or branched-pentoxy, straight- or branched-hexyloxy, straight- or
branched-
heptyloxy or straight- or branched-octyloxy. Preferably, C,-C$-alkoxy is C,-C4-
alkoxy.
"C,-C8-HaloalkyP" and "C,-C8-haloalkoxy" denote C,-C8-alkyl and C,-C8-alkoxy,
as
hereinbefore defined, substituted by one or more halogen atoms, preferably
one, two or three
halogen atoms, preferably fluorine, bromine or chlorine atoms. Preferably, C,-
C8-haloalkyl is
C,-C4-alkyl substituted by one, two or three fluorine, bromine or chlorine
atoms. Preferably,
C,-C8-haloalkoxy is C,-C4-alkoxy substituted by one, two or three fluorine,
bromine or
chlorine atoms.
"C,-CB-AIkylsulfonyP", as used herein, denotes C,-C8-alkyl, as hereinbefore
defined,
linked to -SO2-. Preferably, C,-CB-alkylsulfonyl is C,-C4-alkylsulfonyl,
especially
methylsulfonyl.
"Amino-C,-C8-aIkyP" and "amino-C,-C8-alkoxy" denote amino attached by a
nitrogen
atom to C,-C8-alkyl, e.g., NH2-(C,-C8)-, or to C,-C$-alkoxy, e.g., NH2-(C,-C8)-
0-, respectively,
as hereinbefore defined. Preferably, amino-C,-C8-alkyl and amino-C,-C8-alkoxy
are,
respectively, amino-C,-C4-alkyl and amino-C,-C4-alkoxy.
-6-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
"Amino-(hydroxy)-C,-C8-aIkyl" denotes amino attached by a nitrogen atom to
C,-C8-alkyl and hydroxy attached by an oxygen atom to the same C,-C8-alkyl.
Preferably,
amino-(hydroxy)-C,-C8-alkyl is amino-(hydroxy)-CZ-C4-alkyl.
"Carboxy-C,-C$-alkyP" and "carboxy-C,-C8-alkoxy" denote carboxy attached by a
carbon atom to C,-Cg-alkyl or C,-C8-alkoxy, respectively, as hereinbefore
defined.
Preferably, carboxy-C,-CB-alkyl and carboxy-C,-C8-alkoxy are, respectively,
carboxy-C,-C4-
alkyl and carboxy-C,-C4-alkoxy.
"C,-C8-Alkylcarbonyl", "C,-C8-alkoxycarbonyl "and "C,-C8-haloalkylcarbonyP"
denote
C,-C$-alkyl, C,-C$-alkoxy or C,-CB-haloalkyl, respectively, as hereinbefore
defined, attached
by a carbon atom to a carbonyl group. "C,-C8-Alkoxycarbonyl" denotes C,-C8-
alkoxy, as
hereinbefore defined, wherein the oxygen of the alkoxy group is attached to
the carbonyl
carbon. Preferably, C,-CB-alkylcarbonyl, C,-CB-alkoxycarbonyl and C,-C8-
haloalkylcarbonyl
are, respectively, C,-C4-alkylcarbonyl, C,-C4-alkoxycarbonyl and C,-C4-
haloalkylcarbonyl.
"C,-C8-Alkylamino" and "di(C,-Ca-alkyl)amino" denote C,-C8-alkyl, as
hereinbefore
defined, attached by a carbon atom to an amino group. The C,-C8-alkyl groups
in
di(C,-C$-alkyl)amino may be the same or different. Preferably, C,-C$-
alkylamino and
di(C,-C$-alkyl)amino are, respectively, C,-C4-alkylamino and di(C,-C4-
alkyl)amino.
"C,-C$-AlkylaminocarbonyP" and "di(C,-C8-alkyl)aminocarbonyl" denote
C,-C8-alkylamino and di(C,-C8-alkyl)amino, respectively, as hereinbefore
defined, attached
by a nitrogen atom to the carbon atom of a carbonyl group. Preferably,
C,-C8-alkylaminocarbonyl and di(C,-C8-alkyl)-aminocarbonyl are, respectively,
C,-C4-alkylaminocarbonyl and di(C,-C4-alkyl)-aminocarbonyl.
As used herein, the term "4- to 10-membered heterocyclic group" is intended to
mean
a stable monocyclic or bicyclic heterocyclic ring which is saturated,
partially unsaturated or
unsaturated (aromatic), and which consists of at least one ring heteroatom
selected from the
group consisting of nitrogen, oxygen and sulphur, e.g., furan,
tetrahydrofuran, pyrrole,
pyrrolidine, pyrazole, imidazole, triazole, isotriazole, tetrazole,
thiadiazole, isothiazole,
oxadiazole, pyridine, oxazole, isoxazole, pyrazine, pyridazine, pyrimidine,
piperidine,
piperazine, morpholine, thiomorpholine, triazine, oxazine, thiazole,
quinoline, isoquinoline,
benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole,
benzofuran,
indole, indazole or benzimidazole. Preferred heterocyclic groups include
piperazine,
-7-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
morpholine, thiomorpholine, imidazole, isotriazole, pyrazole, pyridine,
pyrrolidine, furan,
oxazole, oxadiazole, isoxazole, thiazole, tetrazole benzothiophene,
benzoxazole,
benzothiazole and benzofuran. The 4- to 10-membered heterocyclic group can be
unsubstituted or substituted. Preferred substituents include halo, cyano, oxo,
hydroxy,
carboxy, nitro, C,-C8-alkyl optionally substituted by cyano, C,-C8-
alkylcarbonyl, hydroxy-
C,-CB-alkyl, C,-C$-haloalkyl, amino-C,-C$-alkyl, C,-C8-alkylamino, di(C,-C8-
alkyl)amino
amino(hydroxy)C,-C8-alkyl and C,-C$-alkoxy optionally substituted by
aminocarbonyl.
Especially preferred substituents include halo, oxo, C,-C4-alkyl, C,-C4-
alkylcarbonyl, hydroxy-
C,-C4-alkyl, C,-C4-haloalkyl, amino-C,-C,-alkyl and amino(hydroxy)C,-C4-alkyl.
Throughout
this specification and in the claims that follow, unless the context requires
otherwise, the
word "comprise", or variations, such as "comprises" or "comprising", will be
understood to
imply the inclusion of a stated integer or step or group of integers or steps
but not the
exclusion of any other integer or step or group of integers or steps.
Many of the compounds represented by formula (I) are capable of forming acid
addition salts, particularly pharmaceutically acceptable acid addition salts.
Pharmaceutically
acceptable acid addition salts of the compound of formula (I) include those of
inorganic
acids, e.g., hydrohalic acids, such as hydrochloric acid or hydrobromic acid;
nitric acid;
sulphuric acid; phosphoric acid; and organic acids, e.g., aliphatic
monocarboxylic acids, such
as formic acid, acetic acid, diphenylacetic acid, triphenylacetic acid,
caprylic acid,
dichloroacetic acid, trifluoroacetic acid, hippuric acid, propionic acid and
butyric acid;
aliphatic hydroxy acids, such as lactic acid, citric acid, gluconic acid,
mandelic acid, tartaric
acid or malic acid; dicarboxylic acids, such as adipic acid, aspartic acid,
fumaric acid,
glutamic acid, maleic acid, malonic acid, sebacic acid or succinic acid;
aromatic carboxylic
acids, such as benzoic acid, p-chlorobenzoic acid, or nicotinic acid; aromatic
hydroxy acids,
such as o-hydroxybenzoic acid, p-hydroxybenzoic acid, 1-hydroxynaphthalene-2-
carboxylic
acid or 3-hydroxynaphthalene-2-carboxylic acid; and sulfonic acids, such as
ethanesulfonic
acid, ethane-1,2-disulfonic acid, 2-hydroxyethanesulfonic acid,
methanesulfonic acid,
(+)-camphor-1 0-sulfonic acid, benzenesulfonic acid, naphthalene-2-sulfonic
acid,
naphthalene-1,5-disulfonic acid or p-toluenesulfonic acid. These salts may be
prepared from
compounds of formula (I) by known salt-forming procedures.
Compounds of formula (I) which contain acidic, e.g., carboxyl, groups, are
also
capable of forming salts with bases, in particular, pharmaceutically
acceptable bases, such
as those well-known in the art; suitable such salts include metal salts,
particularly, alkali
-8-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
metal or alkaline earth metal salts, such as sodium, potassium, magnesium,
calcium or zinc
salts; or salts with ammonia or pharmaceutically acceptable organic amines or
heterocyclic
bases, such as benethamine, benzathine, diethanolamine, ethanolamine,
4(2-hydroxyethyl)morpholine,1-(2-hydroxyethyl)pyrrolidine, N-methyl glucamine,
piperazine,
triethanolamine or tromethamine. These salts may be prepared from compounds of
formula (I) by known salt-forming procedures.
In those compounds where there is an asymmetric carbon atom or an axis of
chirality
the compounds exist in individual optically active isomeric forms or as
mixtures thereof, e.g.,
as racemic or diastereomeric mixtures. The present invention embraces both
individual
optically active R and S isomers, as well as mixtures, e.g., racemic or
diastereomeric
mixtures thereof.
Specific especially preferred compounds of formula (I) include those
hereinafter
described in the Examples.
Since prodrugs are known to enhance numerous desirable qualities of
pharmaceuticals, e.g., solubility, bioavailability, manufacturing, etc., the
compounds of the
present invention may be delivered in prodrug form. Thus, the present
invention is intended
to cover prodrugs of the presently claimed compounds, methods of delivering
the same and
compositions containing the same. "Prodrugs" are intended to include any
covalently
bonded carriers which release an active parent drug of the present invention
in vivo when
such prodrug is administered to a mammalian subject. Prodrugs of the present
invention are
prepared by modifying functional groups present in the compound in such a way
that the
modifications are cleaved, either in routine manipulation or in vivo, to the
parent compound.
Prodrugs include compounds of the present invention wherein a hydroxy, amino
or sulfhydryl
group is bonded to any group that, when the prodrug of the present invention
is administered
to a mammalian subject, it cleaves to form a free hydroxyl, free amino or free
sulfhydryl
group, respectively. Examples of prodrugs include, but are not limited to,
acetate, formate
and benzoate derivatives of alcohol and amine functional groups in the
compounds of the
present invention.
"Therapeutically effective amount" is intended to include an amount of a
compound of
the present invention alone or an amount of the combination of compounds
claimed or an
amount of a compound of the present invention in combination with other active
ingredients
effective to treat the inflammatory diseases described herein.
-9-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
As used herein, "treating" or "treatment" cover the treatment of a disease-
state in a
mammal, particularly in a human, and include:
(a) preventing the disease-state from occurring in a mammal, in particular,
when
such mammal is predisposed to the disease-state but has not yet been diagnosed
as
having it;
(b) inhibiting the disease-state, i.e., arresting it development; and/or
(c) relieving the disease-state, i.e., causing regression of the disease
state.
Synthesis
Another embodiment of the present invention provides a process for the
preparation
of compounds of formula (I) in free or pharmaceutically acceptable salt form,
which
comprises the steps of:
(i) (A) for the preparation of compounds of formula (I),
wherein R' is R'aS-, R'aO- or RaNR9,
Rle Rtc
HO
~
wherein R'a is O
and all other symbols are as hereinbefore defined;
(B) cleaving an ester group -COOR8 in a compound of formula (I),
wherein R' is R'aS-, R'a0- or R'aNR9,
Rte Rlc
R80
wherein R'a is 0 ; and
R8 is selected from C,-C8-alkyl, C3-C15-cycloalkyl, C,-CB-alkyl(C6-Ct5-
aromatic
carbocyclic group), and C6-C15-aromatic carboxylic group; and
all other symbols are as hereinbefore defined; and
(ii) recovering the resultant compound of formula (I), in free or
pharmaceutically
acceptable salt form.
-10-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
The process for the preparation of compounds of formula (I) may be carried out
using
known procedures for ester cleavage or analogously as hereinafter described in
the
Examples.
Starting materials for the process for the preparation of compounds of formula
(I), and
compounds for the preparation of those starting materials, may be novel or
known; they may
be prepared in accordance with known procedures or analogously as hereinafter
described
in the Examples.
The compounds of formula (I) can be prepared, e.g., using the reactions and
techniques described below. The reactions may be performed in a solvent
appropriate to the
reagents and materials employed and suitable for the transformations being
effected. It will
be understood by those skilled in the art of organic synthesis that the
functionality present on
the molecule should be consistent with the transformations proposed. This will
sometimes
require a judgment to modify the order of the synthetic steps or to select one
particular
process scheme over another in order to obtain a desired compound of the
invention.
The various substituents on the synthetic intermediates and final products
shown in
the following reaction schemes can be present in their fully elaborated forms,
with suitable
protecting groups where required as understood by one skilled in the art, or
in precursor
forms which can later be elaborated into their final forms by methods familiar
to one skilled in
the art. The substituents can also be added at various stages throughout the
synthetic
sequence or after completion of the synthetic sequence. In many cases,
commonly used
functional group manipulations can be used to transform one intermediate into
another
intermediate, or one compound of formula (I) into another compound of formula
(I).
Examples of such manipulations are conversion of an ester or a ketone to an
alcohol;
conversion of an ester to a ketone; interconversions of esters, acids and
amides; alkylation,
acylation and sulfonylation of alcohols and amines; and many others.
Substituents can also
be added using common reactions, such as alkylation, acylation, halogenation
or oxidation.
Such manipulations are well-known in the art, and many reference works
summarize
procedures and methods for such manipulations. Some reference works which
gives
examples and references to the primary literature of organic synthesis for
many functional
group manipulations, as well as other transformations commonly used in the art
of organic
synthesis are March's Organic Chemistry, 5th Edition, Wiley and Chichester,
Eds. (2001);
Comprehensive Organic Transformations, Larock, Ed., VCH (1989); Comprehensive
Organic
-11-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Functional Group Transformations, Katritzky et al. (series editors), Pergamon
(1995); and
Comprehensive Organic Synthesis, Trost and Fleming (series editors), Pergamon
(1991).
Generally, compounds described in the scope of this patent application can be
synthesized by the routes described in Schemes 1 and 2.
In Scheme 1, alkylation of a substituted phenol 1 with a haloacetate ester
(preferably
methyl bromoacetate) in the presence of an inorganic base generates
intermediate 2.
Reduction of the aldehyde moiety of intermediate 2 with sodium borohydride
provides the
alcohol derivative 3. Bromination of alcohol derivative 3 with phosphorus
tribromide provides
intermediate 4. Next, intermediate 4 is coupled with an aromatic boronic acid
using a
palladium catalyst to generate intermediate 5. Alkylation of intermediate 5
with a
halocarboxylate ester (preferably tert-butyl bromopropionate) yields the tert-
butyl ester
derivative 6. Subsequent cleavage of the tert-butyl ester affords 7 which can
be transformed
into a cyclic amide 8 using a cyclic secondary amine and polymer supported
carbonyl
diimidazole and N-hydroxybenzotriazole in acetonitrile with microwave
irradiation according
to Org Lett, Vol. 5, p. 4721 (2003). Finally hydrolysis provides compound 9.
-12-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Scheme I
O O~-, O O O 011-1
OH O 'Y 'T
O TO O O
H alkYlation \ \ \
H reduction OH brom m~ Br
R 4 R4 Ra Ra
1 2 3 q
coupling
O O O OH O O\ 0 0
O O~
O O x T
O O O OH
hydrolysis alkylation 4 7 RS R4 R5 Ra Re
6 5
H
U
O 'Y O 0 N O 'Y OH O N
O O O O
1hydrolysis ( \ I \
/
R R5 R5
8 9
-13-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Alternatively, as depicted in Scheme 2, when R4 and R5 are the same,
intermediate 10 can be selectively alkylated using a bromoacetate derivative,
such as benzyl
bromoactetate, according to the procedure of Synlett, p. 199 (2003) to provide
intermediate 11. From intermediate 11, intermediates 12, 13, 14 and compound
15 can be
generated similar to the procedures described in Scheme 1.
Scheme 2
\ !
~ 0 0 o~
0 T 0 0
OH OH O OH O O
\ alkylation _ I\ I\ alkylation _ I\ I\
R 10 Rs Ra 11 Rs Rn Rs
12
hydrolysis
\ I \ I
O 'T OH O N O T O O N O O O OH O O O O O-T O
I\ I\ hydrolysis I\ I\ ' \H I\ I\
R5 4 R5 5
15 14 13
-14-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
EXAMPLES
HO,,,CQ
O Y~
O ~ X ~
R'2 R'3
X=CH2
Y=0
Example R12 R13 Q MH+
I CI CI CH3 452
N
0
2 CI CI CH 452 (1)
3 452 (2)
N
0
3 CI C{ 468
CH3 O
N
0
4 CI CI 466
CH3
N
0
CI H CH3 486
~
..~N
6 CI H CH ~N-CH3 447
L 3 N
O
-15-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Example R12 R13 Q MH+
7 CI H CH 3 418
L(NIIII O
8 CI H CH 418 (1)
3
N 418(2)
O
9 CI H 432
Ci H3
N
O
CI CI r Ni-CH3 467
-yN
O
General conditions
LCMS are recorded on an Agilent 1100 LC system with a Waters Xterra MS C18
4.6 x 100 5 pM column, eluting with 5-95% 10 mM aqueous ammonium bicarbonate
in
acetonitrile over 2.5 minutes, with negative ion electrospray ionization or 5-
95% water + 0.1 %
TFA in acetonitrile with positive ion electrospray ionization. MH+ refer to
monoisotopic
molecular weights.
Melting points (m.p.) are uncorrected.
NMR are recorded at 400 MHz in CDCI3i unless otherwise noted. The EmrysTM
Optimiser
microwave instrument (PersonalChemistry AB) is used in the standard
configuration as
delivered.
Abbreviations
-16-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
-17-
CHCI3 chloroform MgSO4 magnesium sulfate
DCM dichloromethane NaHCO3 sodium bicarbonate
DIPEA diisopropylethylamine NaH sodium hydride
DMAP 4-(dimethylamino)pyridine NaOH sodium hydroxide
DME 1,2-dimethoxyethane Na2SO4 sodium sulfate
DMF dimethylformamide Pd(PPh3)4 tetrakis(triphenylphosphine)
palladium(O)
EtOAc ethyl acetate PS-CDI polymer supported carbodiimide
HATU O-(7-azabenzotriazol-1-yl)- PS-EDC polymer supported 1-(3-
N,N,N;N'tetramethyluronium
dimethylaminopropyl)-3-
hexafluorophophate dimethylaminopropyl)-3-
ethylcarbodiimide
HCI hydrochloric acid RT room temperature
HOAT 1 -hydroxy-7-azabenzotriazole TEA triethylamine
HOBt 1 -hydroxybenzotriazole TFA trifluoroacetic acid
HPLC high performance liquid
chromatography THF tetrahydrofuran
IPA iso-propyl alcohol
MeOH methanol
Preparation of Intermediates
Intermediate A
2-f2-(2-Benzyloxycarbonylmethoxy-5-chloro-benzyl)-4-chloro-phenoxyl-propionic
acid
Al) Preparation of [4-chloro-2-(5-chloro-2-hydroxy-benzyl)-phenoxy]-acetic
acid
benzyl ester
2,2'-Methylene-bis(4-chloro-phenol) (12 g, 44.6 mmol) is dissolved in DMF (100
mL).
Lithium carbonate (3.3 g, 44.6 mmol) is added, followed by benzyl-2-
bromoacetate (7.7 mL,
49 mmol). The suspension is stirred at 80 C for 8 hours. Further benzyl-2-
bromoacetate
(1 mL, 6.4 mmol) is added and stirring continued at 100 C for 4 hours. The
reaction mixture
is evaporated to dryness, water is added to the residue which is acidified to
pH 1 with 2 M
aqueous HCI and extracted with EtOAc. The organic layer is washed with brine,
dried
(MgSO4) and evaporated. The crude product is purified by flash column
chromatography
over silica gel eluting with 4:1 iso-hexane:EtOAc. The product is suspended in
iso-hexane,
dissolved in the minimum volume of EtOAc, seeded and left to stand. The
resultant solid is
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
collected by filtration, washed with iso-hexane and dried to give [4-chloro-2-
(5-chloro-2-
hydroxy-benzyl)-phenoxy]-acetic acid benzyl ester; m.p. = 135-137 0.
A2) Preparation of 2-[2-(2-benzyloxycarbonylmethoxy-5-chloro-benzyl)-4-chloro-
phenoxy]-propionic acid tert-butyl ester
To a solution of 2-bromopropionic acid tert-butyl ester (0.827 g, 3.95 mmol)
in DMF
(15 mL) is added [4-chloro-2-(5-chloro-2-hydroxy-benzyl)-phenoxy]-acetic acid
benzyl ester
(1.5 g, 3.60 mmol) and potassium carbonate (0.547 g, 3.95 mmol). The reaction
mixture is
stirred at RT overnight and the solvent is removed in vacuo. The crude product
is dissolved
in EtOAc (50 mL) and washed with water (50 mL) and brine (50 mL). The organic
portion is
dried (MgSO4) and concentrated in vacuo to yield a yellow oil which is dried
in a vacuum
oven for 2 hours to afford the titled product which is used in the next step
without purification.
A3) Preparation of 2-[2-(2-benzyloxycarbonylmethoxy-5-chloro-benzyl)-4-chloro-
phenoxy]-propionic acid
A solution of 2-[2-(2-benzyloxycarbonylmethoxy-5-chloro-benzyl)-4-chloro-
phenoxy]-
propionic acid tert-butyl ester (1.736 g, 3.18 mmol) in DCM (10 mL) is treated
with TFA
(5 mL) and allowed to stir at RT for 1 hour. The solvent is removed in vacuo
to yield the titled
compound as an off-white solid.
Intermediate B
2-(2-(5-Chloro-2-methoxycarbonylmethoxy-benzyl)-phenoxyl-propionic acid
131) Preparation of (2-bromomethyl-4-chloro-phenoxy)-acetic acid methyl ester
To a cooled (0 C) solution of (4-chloro-2-hydroxymethyl-phenoxy)-acetic acid
methyl
ester (5 g, 0.022 mmol) in DCM (50 mL) under an inert atmosphere of nitrogen
is added
phosphorus tribromide (1.03 mL, 0.011 mol) and the mixture is stirred at 0 C
for 90 minutes.
The reaction mixture is diluted with water (15 mL) and allowed to warm to RT.
The mixture is
then washed with water (2 x 25 mL) and the organic portion is separated,
washed with brine,
dried (MgSO4) and concentrated in vacuo to yield the titled compound as a
white solid.
B2) Preparation of [4-chloro-2-(2-hydroxy-benzyl)-phenoxy]-acetic acid methyl
ester
(i) A solution of 2 M Na2CO3 (70 mL, 0.053 mol) is treated with 2-
hydroxyphenyl
boronic acid (9.7 g, 0.074 mol) in DME (200 mL). To this mixture is added
bis(triphenylphosphine)palladium (II) chloride (3.24 g, 4.72 mmol) followed by
(2-bromomethyl-4-chloro-phenoxy)-acetic acid methyl ester in DME (200 mL) and
the
-18-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
reaction mixture is heated to reflux overnight. After cooling to RT, the
reaction mixture is
filtered through Celite and concentrated in vacuo to yield a 1:1 mixture of
[4-chloro-2-(2-
hydroxy-benzyl)-phenoxy]-acetic acid and [4-chloro-2-(2-hydroxy-benzyl)-
phenoxy]-acetic
acid methyl ester.
(ii) A solution comprising a 1:1 mixture of [4-chloro-2-(2-hydroxy-benzyl)-
phenoxy]-
acetic acid and [4-chloro-2-(2-hydroxy-benzyl)-phenoxy]-acetic acid methyl
ester (3.32 g,
0.011 mol - approx.) in methanol (70 mL) is treated dropwise with concentrated
sulphuric
acid (2.2 mL) and heated to reflux for 2 hours. The mixture is cooled to RT
and the solvent is
removed in vacuo. The crude product is dissolved in EtOAc (300 mL) and washed
with
saturated sodium bicarbonate solution (300 mL). The organic layer is separated
and the
aqueous portion is extracted with EtOAc (200 mL). The organic extracts are
combined,
washed with water (300 mL), brine (300 mL), dried MgSO4 and concentrated in
vacuo to
yield a solid which is dried in a vacuum oven at 40 C to yield the titled
product.
B3) Preparation of 2-[2-(5-chloro-2-methoxycarbonylmethoxy-benzyl)-phenoxy]-
propionic acid
The titled compound is prepared analogously to 2-[2-(2-
benzyloxycarbonylmethoxy-5-
chloro-benzyl)-4-chtoro-phenoxy]-propionic acid by replacing [4-chloro-2-(5-
chloro-2-hydroxy-
benzyl)-phenoxy]-acetic acid benzyl ester with [4-chloro-2-(2-hydroxy-benzyl)-
phenoxy]-
acetic acid methyl ester.
Intermediate C
The titled compound is prepared analogously to 2-[2-(2-
benzyloxycarbonylmethoxy-5-
chloro-benzyl)-4-chloro-phenoxy]-propionic acid (Intermediate A) by replacing
2-bromopropionic acid tert-butyl ester with tert-butyl bromoacetate.
Example I
{4-Chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyrrolidin-l-yl-ethoxy)-benzyl]-
phenoxy}-
acetic acid
a) Preparation of {4-chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyrrolidin-1-yl-
ethoxy)-
benzyl]-phenoxy}-acetic acid benzyl ester
To a suspension of 2-[2-(2-benzyloxycarbonylmethoxy-5-chloro-benzyl)-4-chloro-
phenoxy]-propionic acid (Intermediate A) (100 mg, 0.204 mmol), HOBt (27.6 mg,
0.204 mmol) and PS-CDI (326.4 mg,1.25 mmol/g, 0.408 mmol) in acetonitrile (15
mL) is
-19-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
added pyrrolidine (17.1 pL, 0.204 mmol). The reaction mixture is heated using
microwave
radiation in a Personal Chemistry EmrysTM Optimizer microwave reactor at 100 C
for
minutes. The PS-CDI resin is removed by filtration, rinsing with DCM and MeOH
and the
filtrate is concentrated in vacuo. The crude product is dissolved in EtOAc (50
mL) and
washed with water (50 mL), aqueous sodium carbonate solution (30 mL), brine
(50 mL) and
then dried (MgSO4). The solvent is removed in vacuo and purification of the
crude product
by chromatography on silica eluting with EtOAc/iso-hexane (1:4) affords the
titled product as
a racemic mixture; MH+ = 542.
b) Preparation of {4-chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyrrolidin-1-yl-
ethoxy)-
benzyl]-phenoxy}-acetic acid
A solution comprising {4-chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyrrolidin-1-
yl-
ethoxy)-benzyl]-phenoxy}-acetic acid benzyl ester (63 mg, 0.116 mmol) in MeOH
(1 mL) is
treated with 2 M NaOH (145 pL) and allowed to stir at RT overnight. The
resulting
suspension is filtered, dissolved in water (1 mL) and the pH of the solution
is adjusted to
pH 1 using 2 M HCI. A precipitate forms which is filtered and dried in a
vacuum oven to
afford the titled product; MH' = 452.
Example 2
{4-Chloro-2-[5-chloro-2-((R/S)-1-methyl-2-oxo-2-pyrrolidin-1-yl-ethoxy)-
benzyl]-
phenoxy}-acetic acid - Enantiomer I and Enantiomer 2
The enantiomers prepared in Example 1 a are resolved using a chiralcel OD
column
eluting with 30% IPA in hexanes to afford enantiomer A (retention time =
8.44minutes) and
enantiomer B (retention time = 12.7 minutes). Enantiomer 1 is prepared using
an analogous
procedure to {4-chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyrrolidin-1-yI-ethoxy)-
benzyl]-
phenoxy}-acetic acid by replacing the racemic mixture of {4-chloro-2-[5-chloro-
2-(1-methyl-2-
oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-phenoxy}-acetic acid benzyl ester with
enantiomer A;
MH+ = 452. Enantiomer 2 is prepared analogously using the procedure described
above by
replacing Enantiomer A with Enantiomer B; MH+ = 452.
Examples 3 and 4
These compounds namely,
= {4-Chloro-2-[5-chloro-2-(1-methyl-2-morpholin-4-yl-2-oxo-ethoxy)-benzyl]-
phenoxy}-acetic
acid (Example 3); and
-20-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
= {4-Chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-piperidin-1-yl-ethoxy)-benzyl]-
phenoxy}-acetic
acid (Example 4),
are prepared analogously to {4-chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyn-
olidin-1-yl-ethoxy)-
benzyl]-phenoxy}-acetic acid (Example 1) by replacing pyrrolidine with the
appropriate cyclic
amine.
Examples 5-7
These compounds namely,
= [4-Chloro-2-(2-{2-[4-(2-cyano-ethyl)-piperazin-1-yl]-1-methyl-2-oxo-ethoxy}-
benzyl)-
phenoxy]-acetic acid (Example 5);
= (4-Chloro-2-{2-[1-methyl-2-(4-methyl-piperazin-1-yl)-2-oxo-ethoxy]-benzyl}-
phenoxy)-
acetic acid (Example 6); and
= {4-Chloro-2-[2-(1-methyl-2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-phenoxy}-
acetic acid
(Example 7),
are prepared analogously to Example I by replacing 2-[2-(2-
benzyloxycarbonylmethoxy-5-
chloro-benzyl)-4-chloro-phenoxy]-propionic acid (Intermediate A) with 2-[2-(5-
chloro-2-
methoxycarbonylmethoxy-benzyl)-phenoxy]-propionic acid (Intermediate B) and by
replacing
pyrrolidine with the appropriate cyclic amine.
Example 8
{4-Chloro-2-[2-((R/S)-1-methyl-2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-
phenoxy}-acetic
acid - Enantiomer I and Enantiomer 2
These compounds are prepared analogously to Example 2 by chiral resolution of
the
precursor racemate ({4-chloro-2-[2-(1-methyl-2-oxo-2-pyrrolidin-1-yi-ethoxy)-
benzyl]-
phenoxy}-acetic acid methyl ester) to produce Enantiomer C (Retention time =
5.93 minutes)
and Enantiomer D (Retention time = 7.66 minutes). Enantiomer C and Enantiomer
D are
then hydrolyzed using the conditions described in Example 1 b to afford
Enantiomer 2 and
Enantiomer 1, respectively.
-21-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Example 9
{4-Chloro-2-[2-(1-methyl-2-oxo-2-piperidin-1-yl-ethoxy)-benzyl]-phenoxy}-
acetic acid
a) Preparation of {4-chtoro-2-[2-(1-methyl-2-oxo-2-piperidin-l-yl-ethoxy)-
benzyi]-
phenoxy}-acetic acid methyl ester
To a solution of PS-EDC (0.558 g, 1.42 mmol/g, 0.792 mmol) in DMF (2 mL) is
added
2-[2-(5-chloro-2-methoxycarbonylmethoxy-benzyl)-phenoxyj-propionic acid
(Intermediate B)
(150 mg, 0.396 mmol) in DMF (2 mL) and HOAT (80.8 mg, 0.594 mmol) in DMF (2
mL). The
reaction mixture is agitated for 50 minutes and then treated with piperidine
(39.2 pL,
0.396 mmol) and agitated at RT for 2 days. Polymer supported trisamine (0.475
g,
1.42 mmol/g, 1.98 mmol) is then added and the mixture is further agitated
overnight. The
reaction mixture is filtered to remove the resins and rinsed with methanol and
DCM. The
filtrate is reduced in vacuo and the crude solid is re-dissolved in DCM and
washed with
water. The organic portion is separated using a phase separator and
concentrated in vacuo
to yield a solid which is purified by chromatography on silica eluting with
EtOAc/iso-hexane
(30% increasing to 50% EtOAc) to yield the titled product as a pale yellow
oil; MH = 446.
b) Preparation of {4-chloro-2-[2-(1-methyl-2-oxo-2-piperidin-1-yl-ethoxy)-
benzyl]-
phenoxy}-acetic acid
The titled compound is prepared analogously to {4-chloro-2-[5-chloro-2-(1-
methyl-2-
oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-phenoxy}-acetic acid (Example 1) by
replacing
{4-chloro-2-[5-chloro-2-(1-methyl-2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzyl]-
phenoxy}-acetic acid
benzyl ester with {4-chforo-2-[2-(1-methyl-2-oxo-2-piperidin-1-yl-ethoxy)-
benzyl]-phenoxy}-
acetic acid methyl ester; MH' = 432.
Example 10
(4-Chloro-2-{5-chloro-2-[2-(4-methyl-piperazin-l-yl)-2-oxo-ethoxy]-benzyl}-
phenoxy)-
acetic acid trifluoroacetate
a) Preparation of (4-chloro-2-{5-chloro-2-[2-(4-methyl-piperazin-1-yl)-2-oxo-
ethoxy]-benzyl}-phenoxy)-acetic acid benzyl ester
To a solution of [2-(2-benzyloxycarbonylmethoxy-5-chloro-benzyl)-4-chloro-
phenoxy]-
acetic acid (Intermediate C) (0.1 g, 0.211 mmol) in DCM (1 mL) is added DIPEA
(37 pL,
0.211 mmol) and HATU (80 mg, 0.211 mmol). After stirring at RT for 1 hour, the
reaction
mixture is treated with 1-methyl piperidine (24 pL, 0.211 mmol) and allowed to
stir at RT for
-22-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
2 days. The resulting solution is purified by chromatography on silica eluting
with
EtOAc/MeOH (95:5) to yield the titled product.
b) Preparation of (4-chloro-2-(5-chloro-2-[2-(4-methyl-piperazin-1-yi)-2-oxo-
ethoxy]-benzyl)-phenoxy)-acetic acid trifluoroacetate
To a solution of (4-chloro-2-{5-chloro-2-[2-(4-methyl-piperazin-1-yl)-2-oxo-
ethoxy]-
benzyl)-phenoxy)-acetic acid benzyl ester (76 mg, 0.137 mmol) in MeOH (1 mL)
is added
2 M NaOH (137 NL) and the reaction mixture is stirred at RT for 3 days. The
solvent is
removed in vacuo and the resulting crude product is dissolved in water (5 mL).
The pH of
the solution is adjusted by addition of HCI to form a precipitate which is
purified by
preparative HPLC to afford the titled product; MH+ = 467.
Pharmaceutical Use and Assay
Compounds of formula (I) and (Ia) and their pharmaceutically acceptable salts,
hereinafter referred to alternatively as "agents of the invention", are useful
as
pharmaceuticals. In particular, the compounds have good CRTh2 receptor
antagonist activity
and may be tested in the following assays.
Filtration binding assay protocol
The binding of CRTh2 antagonists is determined using membranes prepared from
human CRTh2-expressing Chinese Hamster Ovary cells (CHO.K1-CRTh2). To produce
cell
membranes CHO.K1-CRTh2 cells cultured in roller bottles are harvested using
cell
dissociation buffer (Invitrogen). The cells are pelleted by centrifugation
(167 g, 5 minutes).
The cell pellet is incubated in hypotonic buffer (15 mM Tris-OH, 2 mM MgCIZ,
0.3 mM EDTA,
1 mM EGTA, 1 x CompleteTM tablet) at 4 C for 30 minutes. At 4 C cells are
homogenized
using a Polytron (IKA Ultra Turrax T25) for 5 bursts of 1 second. The
homogenate is
centrifuged (Beckman Optima TM TL Ultracentrifuge, 48,000 g, 30 minutes at 4
C). The
supernatant is discarded and the membrane pellet re-suspended in
homogenisation buffer
(75 mM Tris-OH, 12.5 mM MgCIZ, 0.3 mM EDTA, 1 mM EGTA, 250 mM Sucrose, 1 x
Complete"" tablet. Membrane preparations are aliquoted and stored at 80 C. The
protein
content is estimated using Bradford Protein Assay Dye (Bio Rad).
The binding of [3H]-PGDz (157 Ci/mmol) to CHO.K1-CRTh2 membranes is determined
in the absence (total binding) and presence (non-specific binding) of
unlabelled PGD2 (1 NM).
Subtraction of the cpm (counts per minute) of [3H]-PGD2 binding in presence of
excess
-23-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
unlabelled PGD2 from that observed in the absence of excess uniabelled PGD2 is
defined as
specific binding. Active CRTh2 antagonists are able to compete with [3H]-PGD2
for binding to
the CRTh2 receptor and are identified in a decrease in the number of cpm
bound.
The assay is performed in Greiner U-bottomed 96 well-plates, in a final volume
of
100 NUwell. CHO.K1-CRTh2 membranes were diluted in assay buffer (10 mM HEPES-
KOH
(pH 7.4), 1 mM EDTA and 10 mM MnCI2) and 10 N g are added to each well. [3H]-
PGD2 is
diluted in assay buffer and added to each well at a final concentration of 2.5
nM. To
determine non-specific binding, [3H]-PGD2 binding to the CRTh2 receptor is
competed with
using uniabelled PGD2 at a final well concentration of 1 pM. The experiment is
done in
triplicate, with reagents added to the wells as follows:
= 25 pL assay buffer for total binding or
= 25 pL PGD2 to determine non-specific binding
= 25 pL [3H]PGD2
= 50 pL membranes
= 25 pL test compound in DMSO/assay buffer
The plates are incubated at RT on a shaker for 1 hour, and then harvested
(Tomtec
Harvester 9600) onto GF/C filter plates using wash buffer (10 mM HEPES-KOH, pH
7.4).
The plate is dried for 2 hours, prior to addition of Micro-Scint 20T"" (50 NL)
and sealing with
TopSeal-STM. Plates are then counted using a Packard Top Count instrument,
Plates are
then read on the Packard Topcount with the 3H Scintillation program (1
minute/well).
Ki (dissocation constant for the inhibition) values for the CRTh2 antagonists
are
reported. Ki values are determined using Sigma PlotTM software, using the
Cheng-Prussoff
equation.
Ki = IC50 / 1+ [S]/Kd ,
where S is the concentration of radioligand and Kd is the dissociation
constant.
CRTH2 cAMP functional assay protocol
This assay is conducted in CHO.K1-CRTh2 cells. cAMP is generated in the cell
by
stimulating cells with 5 pM forskolin, an adenylate cyclase activator. PGD2 is
added to
activate the CRTh2 receptor which results in the attenuation of the forskolin-
induced cAMP
accumulation. Potential CRTh2 antagonists are tested for their ability to
inhibit the PGD2-
mediated attenuation of the forskolin-induced cAMP accumulation in CHO.K1-
CRTh2 cells.
-24-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
For each concentration value on the dose-response curve, test compounds are
prepared in assay stimulation buffer (HBSS, 5 mM HEPES, 10 pM IBMX 0.1%
human
serum albumin) containing DMSO (3% vol/vol) and 5 NUwell is added to an assay
plate
(384-well white optiplate).
CHO. K1-CRTh2 cultured in tissue culture flasks are washed with PBS and
harvested
with dissociation buffer. Cells are washed with PBS and resuspended in
stimulation buffer to
a concentration of 0.4 x 106/mL and added to the assay plate (10 NUwell).
The assay plate is incubated at room temperature on a shaker for 15 minutes.
A mix of agonist (10 nM Prostaglandin DZ) and 5 pM forskolin is prepared in
assay
stimulation buffer and added to the assay plate (5 NUwell).
In addition, a cAMP standard is serially diluted in assay stimulation buffer
and added
to separate empty wells on the assay plate (20 pUwell). The cAMP standard
allows for the
quantification of cAMP generated in CHO.K1-CRTH2 cells.
The assay plate is incubated at room temperature on a shaker for 60 minutes.
Cell lysis buffer (Lysis buffer: Milli-Q H20, 5 mM HEPES, 0.3% Tween-20, 0.1 %
human serum albumin) is added to a bead mix (containing AlphascreenTM anti-
cAMP
acceptor beads 0.06 units/pL, AlphascreenTM streptavidin-coated donor beads
0.06 units/pL,
biotinylated cAMP 0.06 units/pL, 10 pM IBMX) is prepared under darkened
conditions
60 minutes prior to addition to the assay plate. The resulting lysis mix is
added to all wells of
the assay plate (40 NL/well).
The assay plate is sealed with Topseal-ST"" and incubated in the dark at room
temperature on a shaker for 45 minutes. The plate is then counted using a
Packard
FusionTM instrument.
The resulting counts per minute are converted to nM cAMP by using the prepared
cAMP standard curve. IC50 values (concentration of CRTh2 antagonist required
to inhibit
50% of the PGD2-mediated attenuation of forskolin-induced cAMP accumulation in
CHO.K1-
CRTh2 cells) are then determined using PrismTM software.
Compounds of the Examples herein generally have Ki values in the SPA binding
assay below 1 pM. The compounds also generally have IC50 values in the
functional assays
below 1 pM.
-25-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Compounds of the Examples herein below generally have Ki values in the SPA
binding assay below 1 pM. For example, the compounds of Examples 1, 3, 7 and 8
(enantiomer 1) have Ki values of 0.0403, 0.0950 0.0824 and 0.0602 pM,
respectively.
Compounds of the Examples herein below generally have IC50 values in the
functional assay below 1 pM. For example, the compounds of Examples 1, 3, 7
and 8
(enantiomer 1) have IC50 values of 0.0225, 0.0225 0.0375 and 0.0250 pM,
respectively.
Compounds of formula (I) and (Ia), in free or salt form, are antagonists of
the
G-protein-coupled chemoattractant receptor CRTh2, expressed on Th2 cells,
eosinophils and
basophils. PGDZ is the natural ligand for CRTh2. Thus, antagonists which
inhibit the binding
of CRTh2 and PGD2 are useful in the treatment of allergic and anti-
inflammatory conditions.
Treatment in accordance with the invention may be symptomatic or prophylactic.
Accordingly, agents of the invention are useful in the treatment of
inflammatory or
obstructive airways diseases, resulting, e.g., in reduction of tissue damage,
airways
inflammation, bronchial hyperreactivity, remodeling or disease progression.
Inflammatory or
obstructive airways diseases to which the present invention is applicable
include asthma of
whatever type or genesis including both intrinsic (non-allergic) asthma and
extrinsic (allergic)
asthma, mild asthma, moderate asthma, severe asthma, bronchitis asthma,
exercise-induced
asthma, occupational asthma and asthma induced following bacterial infection.
Treatment of
asthma is also to be understood as embracing treatment of subjects, e.g., of
less than 4 or
years of age, exhibiting wheezing symptoms and diagnosed or diagnosable as
"wheezy
infants", an established patient category of major medical concern and now
often identified
as incipient or early-phase asthmatics. (For convenience this particular
asthmatic condition
is referred to as "wheezy-infant syndrome".)
Prophylactic efficacy in the treatment of asthma will be evidenced by reduced
frequency or severity of symptomatic attack, e.g., of acute asthmatic or
bronchoconstrictor
attack, improvement in lung function or improved airways hyperreactivity. It
may further be
evidenced by reduced requirement for other, symptomatic therapy, i.e., therapy
for or
intended to restrict or abort symptomatic attack when it occurs, e.g., anti-
inflammatory (e.g.,
corticosteroid) or bronchodilatory. Prophylactic benefit in asthma may, in
particular, be
apparent in subjects prone to "morning dipping". "Morning dipping" is a
recognized asthmatic
syndrome, common to a substantial percentage of asthmatics and characterized
by asthma
attack, e.g., between the hours of about 4-6 a.m., i.e., at a time normally
substantially distant
from any previously administered symptomatic asthma therapy.
-26-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Other inflammatory or obstructive airways diseases and conditions to which the
present invention is applicable include acute lung injury (ALI), adult
respiratory distress
syndrome (ARDS), chronic obstructive pulmonary, airways or lung disease (COPD,
COAD or
COLD), including chronic bronchitis or dyspnea associated therewith,
emphysema, as well
as exacerbation of airways hyperreactivity consequent to other drug therapy,
in particular,
other inhaled drug therapy. The invention is also applicable to the treatment
of bronchitis of
whatever type or genesis including, e.g., acute, arachidic, catarrhal,
croupus, chronic or
phthinoid bronchitis. Further inflammatory or obstructive airways diseases to
which the
present invention is applicable include pneumoconiosis (an inflammatory,
commonly
occupational, disease of the lungs, frequently accompanied by airways
obstruction, whether
chronic or acute, and occasioned by repeated inhalation of dusts) of whatever
type or
genesis including, e.g., aluminosis, anthracosis, asbestosis, chalicosis,
ptilosis, siderosis,
silicosis, tabacosis and byssinosis.
Having regard to their anti-inflammatory activity, in particular, in relation
to inhibition of
eosinophil activation, agents of the invention are also useful in the
treatment of eosinophil
related disorders, e.g., eosinophilia, in particular, eosinophils-related
disorders of the
airways, e.g., involving morbid eosinophilic infiltration of pulmonary tissues
including
hypereosinophilia as it effects the airways and/or lungs, as well as, e.g.,
eosinophil-related
disorders of the airways consequential or concomitant to Loffler's syndrome;
eosinophilic
pneumonia; parasitic, in particular, metazoan, infestation including tropical
eosinophilia;
bronchopulmonary aspergillosis; polyarteritis nodosa including Churg-Strauss
syndrome;
eosinophilic granuloma; and eosinophil-related disorders affecting the airways
occasioned by
drug-reaction.
Agents of the invention are also useful in the treatment of inflammatory or
allergic
conditions of the skin, e.g., psoriasis, contact dermatitis, atopic
dermatitis, alopecia areata,
erythema multiforma, dermatitis herpetiformis, scleroderma, vitiligo,
hypersensitivity angiitis,
urticaria, bullous pemphigoid, lupus erythematosus, pemphisus, epidermolysis
bullosa
acquisita and other inflammatory or allergic conditions of the skin.
Agents of the invention may also be used for the treatment of other diseases
or
conditions, in particular, diseases or conditions having an inflammatory
component, e.g.,
treatment of diseases and conditions of the eye, such as conjunctivitis,
keratoconjunctivitis
sicca and vernal conjunctivitis; diseases affecting the nose including
allergic rhinitis; and
inflammatory disease, in which autoimmune reactions are implicated or having
an
autoimmune component or aetiology, including autoimmune hematological
disorders, e.g.,
-27-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
hemolytic anemia, aplastic anaemia, pure red cell anaemia and idiopathic
thrombocytopenia;
systemic lupus erythematosus; polychondritis; scierodoma; Wegener
granulamatosis;
dermatomyositis; chronic active hepatitis; myasthenia gravis; Steven-Johnson
syndrome;
idiopathic sprue; autoimmune inflammatory bowel disease, e.g., ulcerative
colitis and Crohn's
disease; endocrine opthalmopathy; Grave's disease; sarcoidosis; alveolitis;
chronic
hypersensitivity pneumonitis; multiple sclerosis; primary billiary cirrhosis;
uveitis (anterior and
posterior); keratoconjunctivitis sicca and vernal keratoconjunctivitis;
interstitial lung fibrosis;
psoriatic arthritis; and glomerulonephritis, with and without nephrotic
syndrome, e.g.,
including idiopathic nephrotic syndrome or minal change nephropathy.
Other diseases or conditions which may be treated with agents of the invention
include septic shock; rheumatoid arthritis; osteoarthritis; proliferative
diseases, such as
cancer; atherosclerosis; allograft rejection following transplantation;
stroke; obesity;
restenosis; diabetes, e.g., diabetes mellitus type I(juvenile diabetes) and
diabetes mellitus
type II; diarrheal diseases; ischemia/reperfusion injuries; retinopathy, such
as diabetic
retinopathy or hyperbaric oxygen-induced retinopathy; and conditions
characterized by
elevated intraocular pressure or secretion of ocular aqueous humor, such as
glaucoma.
The effectiveness of an agent of the invention in inhibiting inflammatory
conditions,
e.g., in inflammatory airways diseases, may be demonstrated in an animal
model, e.g., a
mouse or rat model, of airways inflammation or other inflammatory conditions,
e.g., as
described by Szarka et al., J Immunol Methods, Vol. 202, pp. 49-57 (1997);
Renzi et al.,
Am Rev Respir Dis, Vol. 148, pp. 932-939 (1993); Tsuyuki et al., J Clin
Invest, Vol. 96,
pp. 2924-2931 (1995); Cernadas et al., Am J Respir Cell Mol Biol, Vol. 20, pp.
1-8 (1999);
and Williams and Galli, J Exp Med, Vol. 192, pp. 455-462 (2000).
The agents of the invention are also useful as co-therapeutic agents for use
in
combination with other drug substances, such as anti-inflammatory,
bronchodilatory or
antihistamine drug substances, particularly in the treatment of obstructive or
inflammatory
airways diseases, such as those mentioned hereinbefore, e.g., as potentiators
of therapeutic
activity of such drugs or as a means of reducing required dosaging or
potential side effects of
such drugs. An agent of the invention may be mixed with the other drug
substance in a fixed
pharmaceutical composition or it may be administered separately, before,
simultaneously
with or after the other drug substance. Accordingly the invention includes a
combination of
an agent of the invention as hereinbefore described with an anti-inflammatory,
bronchodilatory, antihistamine or anti-tussive drug substance, said agent of
the invention and
said drug substance being in the same or different pharmaceutical composition.
-28-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
Such anti-inflammatory drugs include steroids, in particular,
glucocorticosteroids,
such as budesonide, beciamethasone dipropionate, fluticasone propionate,
ciclesonide or
mometasone furoate; or steroids, described in WO 02/88167, WO 02/12266, WO
02/100879,
WO 02/00679 (especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39,
51, 60, 67, 72,
73, 90, 99 and 101), WO 03/035668, WO 03/048181, WO 03/062259, WO 03/064445
and
WO 03/072592, WO 04/039827, WO 04/066920; non-steroidal glucocorticoid
receptor
agonists, such as those described in WO 00/00531, WO 02/10143 DE 10261874
(2004),
WO 03/082280, WO 03/082787, WO 03/104195, WO 03/101932, WO 04/019935,
WO 04/018429, WO 04/005229, WO 03//086294 and WO 04/26248; LTB4 antagonists,
such
as those described in U.S. Patent No. 5,451,700; LTD4 antagonists, such as
montelukast
and zafirlukast; PDE4 inhibitors, such as cilomilast (Ariflo
GlaxoSmithKline), Roflumilast
(Byk Gulden),V-1 1294A (Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-
Plough),
Arofylline (Almirall Prodesfarma), PD189659 (Parke-Davis), AWD-12-281 (Asta
Medica),
CDC-801 (Celgene), SeICID(TM) CC-10004 (Celgene), KW-4490 (Kyowa Hakko Kogyo),
WO 03/104204, WO 03/104205, WO 04/000814, WO 04/000839 and WO 04/005258
(Merck), as well as those described in WO 98/18796 and WO 03/39544; A2a
agonists, such
as those described in EP 1052264, EP 1241176, EP 409595A2, WO 94/17090,
WO 96/02543, WO 96/02553, WO 98/28319, WO 99/24449, WO 99/24450, WO 99/24451,
WO 99/38877, WO 99/41267, WO 99/67263, WO 99/67264, WO 99/67265, WO 99/67266,
WO 00/23457, WO 00/77018, WO 00/78774, WO 01/23399, WO 01/27130, WO 01/27131,
WO 01/60835, WO 01/94368, WO 02/00676, WO 02/22630, WO 02/96462 and
WO 03/086408; A2b antagonists, such as those described in WO 02/42298; and
beta (R)-2-
adrenoceptor agonists, such as albuterol (salbutamol), metaproterenol,
terbutaline,
salmeterol, fenoterol, procaterol, and especially, formoterol and
pharmaceutically acceptable
salts thereof, and compounds (in free or salt or solvate form) of formula (1)
of WO 00/75114,
which document is incorporated herein by reference, preferably compounds of
the Examples
thereof, especially a compound of formula
O
HN CH3
CH3
HO
N
= H
OH
-29-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
and pharmaceutically acceptable salts thereof, as well as compounds (in free
or salt or
solvate form) of formula (I) of WO 04/16601. Further R-2-adrenoreceptor
agonists include
compounds of JP 05025045, WO 93/18007, WO 99/64035, US 2002/0055651,
WO 01/42193, WO 01/83462, WO/02 66422, WO 02/70490, WO 02/76933, WO 03/024439,
WO 03/072539, WO 03/042160, WO 03/091204, WO 03/042164, WO 03/099764,
WO 04/016578, WO 04/022547, WO 04/032921, WO 04/037773, WO 04/037807,
WO 04/039762, WO 04/039766, WO 04/045618, WO 04/046083, WO 04/033412,
WO 04/037768, WO 04/037773 and EP 1440966.
Such bronchodilatory drugs include anticholinergic or antimuscarinic agents,
in
particular, ipratropium bromide, oxitropium bromide, tiotropium salts and CHF
4226 (Chiesi),
but also those described in WO 01/04118, WO 02/51841, WO 02/53564, WO
03/00840,
WO 03/87094, WO 04/05285, WO 02/00652, WO 03/53966, EP 0424021, U.S. Patent
No. 5,171,744, U.S. Patent No. 3,714,357 and WO 03/33495.
Such co-therapeutic antihistamine drug substances include cetirizine
hydrochloride,
acetaminophen, clemastine fumarate, promethazine, loratidine, desloratidine,
diphenhydramine and fexofenadine hydrochloride.
Combinations of agents of the invention and steroids, 0-2 agonists, PDE4
inhibitors or
LTD4 antagonists may be used, e.g., in the treatment of COPD or, particularly,
asthma.
Combinations of agents of the invention and anticholinergic or antimuscarinic
agents, PDE4
inhibitors, dopamine receptor agonists or LTB4 antagonists may be used, e.g.,
in the
treatment of asthma or, particularly, COPD.
Other useful combinations of agents of the invention with anti-inflammatory
drugs are
those with antagonists of chemokine receptors, e.g., CCR-1, CCR-2, CCR-3, CCR-
4, CCR-5,
CCR-6, CCR-7, CCR-8, CCR-9, CCR-10, CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5;
particularly useful are CCR-3 antagonists, such as those described in WO
2002/026723,
especially 4-{3-[(S)-4-(3,4-dichlorobenzyl)-morpholin-2-ylmethyl]-
ureidomethyl}-benzamide
and those described in WO 2003/077907, WO 2003/007939 and WO 2002/102775.
Also especially useful are CCR-5 antagonists, such as Schering-Plough
antagonists
SC-351125, SCH-55700 and SCH-D; Takeda antagonists, such as N-[[4-[[[6,7-
dihydro-2-(4-
methylphenyl)-5H-benzo-cyclohepten-8-yl]ca rbonyl]amino]phenyl]-
methyl]tetrahydro-N, N-
dimethyl-2H-pyran-4-aminium chloride (TAK-770); and CCR-5 antagonists,
described in U.S.
Patent No. 6,166,037, WO 00/66558 and WO 00/66559.
-30-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
The agents of the invention may be administered by any appropriate route,
e.g.,
orally, e.g., in the form of a tablet or capsule; parenterally, e.g.,
intravenously; by inhalation,
e.g., in the treatment of inflammatory or obstructive airways disease;
intranasally, e.g., in the
treatment of allergic rhinitis; topically to the skin, e.g., in the treatment
of atopic dermatitis; or
rectally, e.g., in the treatment of inflammatory bowel disease.
The present invention also provides a pharmaceutical composition comprising a
compound of formula (I) in free form or in the form of a pharmaceutically
acceptable salt,
optionally together with a pharmaceutically acceptable diluent or carrier
therefore. The
composition may contain a co-therapeutic agent, such as an anti-inflammatory,
bronchodilatory or antihistamine drug as hereinbefore described. Such
compositions may be
prepared using conventional diluents or excipients and techniques known in the
galenic art.
Thus oral dosage forms may include tablets and capsules. Formulations for
topical
administration may take the form of creams, ointments, gels or transdermal
delivery systems,
e.g., patches. Compositions for inhalation may comprise aerosol or other
atomizable
formulations or dry powder formulations.
The present invention also provides for the use of a compound of the present
invention in any of the aforementioned embodiments, in free or
pharmaceutically acceptable
salt form, for the manufacture of a medicament for the treatment of an
inflammatory or
allergic condition, particularly an inflammatory or obstructive airways
disease.
The present invention also provides a method for treating or preventing
inflammatory
or allergic conditions comprising administering to a patient in need thereof a
therapeutically
effective amount of a compound of the present invention, in free or a
pharmaceutically
acceptable salt form.
When the composition comprises an aerosol formulation, it preferably contains,
e.g.,
a hydro-fluoro-alkane (HFA) propellant, such as HFA134a or HFA227 or a mixture
of these,
and may contain one or more co-solvents known in the art, such as ethanol (up
to 20% by
weight); and/or one or more surfactants, such as oleic acid or sorbitan
trioleate; and/or one
or more bulking agents, such as lactose. When the composition comprises a dry
powder
formulation, it preferably contains, e.g., the compound of formula (I) having
a particle
diameter up to 10 microns, optionally together with a diluent or carrier, such
as lactose, of the
desired particle size distribution and a compound that helps to protect
against product
performance deterioration due to moisture. When the composition comprises a
nebulized
formulation, it preferably contains, e.g., the compound of formula (I) either
dissolved, or
-31-
CA 02608375 2007-11-13
WO 2006/125596 PCT/EP2006/004851
suspended, in a vehicle containing water, a co-solvent, such as ethanol or
propylene glycol
and a stabilizer, which may be a surfactant.
The invention includes:
(a) an agent of the invention in inhalable form, e.g., in an aerosol or other
atomizable
composition or in inhalable particulate, e.g., micronized form;
(b) an inhalable medicament comprising an agent of the invention in inhalable
form;
(c) a pharmaceutical product comprising such an agent of the invention in
inhalable
form in association with an inhalation device; and
(d) an inhalation device containing an agent of the invention in inhalable
form.
Dosages of agents of the invention employed in practicing the present
invention will of
course vary depending, e.g., on the particular condition to be treated, the
effect desired and
the mode of administration. In general, suitable daily dosages for oral
administration are of
the order of 0.01-100 mg/kg.
-32-
